ClinicalTrials.gg
Active, not recruitingNCT06019507Updated Nov 27, 2024

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

A Phase 2 interventional study of TCD601 and Cyclophosphamide in Liver Transplantation, sponsored by ITB-Med LLC. Active, not recruiting at 1 site in Sweden. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-27.

Sponsored by ITB-Med LLC · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Jun 2022, registered Aug 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.

02

Conditions studied

  • Liver Transplantation
03

In context

Lead sponsor

ITB-Med LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand the study requirements and provide written before and study assessment is performed
  • Adult subjects aged 18-70 receiving an ABO compatible deceased donor liver transplant
  • Male study subjects willing to maintain barrier (condom) and agree not to father a child until 12 weeks after the last dose of MMF

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing (lactating) women
  • Subjects with a history of TB or latent TB infection
  • Subjects with a history of cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Arm 1

    TCD601administered after liver transplant with splenectomy with cyclophosphamide and immunosuppression therapy

    Biological: TCD601 · Biological: Cyclophosphamide · Drug: TAC · Drug: MMF · Drug: Corticosteroids

Interventions

  • BiologicalTCD601

    Investigational Product

    Also known as: siplizumab

  • Conditioning Regimen

  • DrugTAC

    Immunosuppression Therapy

    Also known as: Tacrolimus

  • DrugMMF

    Immunosuppression Therapy

    Also known as: Mycophenolate Mofetil

  • DrugCorticosteroids

    Immunosuppression Therapy

06

What researchers measure

Primary outcomes

  1. Number of Liver Transplant Recipients off of immunosuppression Therapy.

    Determine if treatment with siplizumab can induce allogeneic tolerance in liver transplant recipients

    Time frame: 30 months

Secondary outcomes

  1. The Incidence of adverse events and serious adverse events

    To explore the safety and tolerability of TCD601.

    Time frame: 30 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Jun 2026, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2023
First posted
Aug 31, 2023
StartActual
Jun 29, 2022
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2029
Last update
Nov 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06019507
Lead sponsor
ITB-Med LLC
Responsible party
Sponsor
First posted
Aug 31, 2023
Start date
Jun 29, 2022
Primary completion
Jun 2026 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 27, 2024

Study contacts

Kellie Kennon, BSN
study director · ITB-MED

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion